Author’s response to reviews

Title: The invasive lobular carcinoma as a prototype luminal A breast cancer: a retrospective cohort study

Authors:

So-Youn Jung (goje1@medimail.co.kr)
Junsoo Jeong (cbr400f@daum.net)
Seung-Ho Shin (sshhere@hanmail.net)
Youngmee Kwon (ymk@ncc.re.kr)
Eun-A Kim (euna25@hanmail.net)
Kyoung Lan Ko (ffrog92@naver.com)
Kyung Hwan Shin (radiat@ncc.re.kr)
Keun Seok Lee (kslee@ncc.re.kr)
In Hae Park (parkih@ncc.re.kr)
Seeyoun Lee (seeyoun@naver.com)
Seok Won Kim (surgeon69@medimail.co.kr)
Han-Sung Kang (rorerr@ncc.re.kr)
Jungsil Ro (jungsro@ncc.re.kr)

Version: 2 Date: 27 August 2010

Author’s response to reviews:

Dear Editor,

I am submitting a manuscript entitled “The invasive lobular carcinoma as a prototype luminal A breast cancer” by So-Youn Jung, Junsoo Jeong, Seung-Ho Shin, Youngmee Kwon, Eun-A Kim, Kyoung Lan Ko, Kyung Hwan Shin, Keun Seok Lee, In Hae Park, Seeyoun Lee, Seok Won Kim, Han-Sung Kang, Jungsil Ro, for publication in BMC Cancer as an original article.

The invasive lobular carcinoma (ILC) is the second most frequent histologic subtype in Western countries. However, its incidence is much lower in Asia, and its characteristics are less well known. Therefore, we analyzed the characteristics of an ILC series and compared the clinical and prognostic parameters with those of invasive ductal carcinoma (IDC).

In our study, the incidence of ILC was 2.8% of invasive breast cancer and the median age and age distribution was not different from IDC. Additionally, we demonstrated a new aspect of ILC after comprehensive data analysis including biologic markers other than general tumor characteristics in the consecutive breast cancer patients. Similar clinicopathological characteristics and clinical outcomes between ILC and the luminal A subtype of IDC (LA-IDC) were discovered after we further compared with the four subtypes of IDC. To our knowledge, this is the first report to show such similarities between ILC and LA-IDC.
This manuscript has not been submitted or being considered for publication in any other journal and we are looking forward to hearing a positive reply from you. Thank you for your kind consideration in advance

Best regards,

Jungsil Ro, M.D.
Center for Breast Cancer, National Cancer Center
323 Ilsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do, 410-769, Korea
Tel) +82-31-920-1610 Fax) +82-31-920-1520
E-mail) jungsro@ncc.re.kr